Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.42 |
| ▸ | MFN2 | O95140 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236810 | 0.92 | MAOA (0.42) | DRD2DRD1TAAR1MAOAMAOB | |
| SCHEMBL613243 | 0.86 | SIGMAR1 (0.43) | SPHK2MAOANMT2NMT1MAOB | |
| SCHEMBL612124 | 0.84 | SIGMAR1 (0.46) | SPHK2MAOANMT2NMT1OPRM1 | |
| SCHEMBL612943 | 0.84 | SIGMAR1 (0.46) | SPHK2MAOANMT2NMT1OPRM1 | |
| SCHEMBL611391 | 0.84 | SPHK2 (0.32) | SPHK2SPHK1TAAR1MAOB | |
| SCHEMBL611144 | 0.80 | PTGER4 (0.47) | SPHK2SPHK1MAOAMAOBOPRM1 | |
| SCHEMBL614399 | 0.80 | SLC6A4 (0.39) | MAOAMAOB | |
| SCHEMBL10455153 | 0.77 | MAOA (0.50) | MFN2MAOAMAOB | |
| SCHEMBL612081 | 0.77 | SLC18A3 (0.39) | SPHK2SPHK1DRD2DRD1TAAR1 | |
| SCHEMBL422194 | 0.76 | MAOA (0.58) | DRD2DRD1TAAR1MAOANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | SPHK2 118/4885SPHK1 161/4885MFN2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.